Cargando…

High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report

Ovarian hyperstimulation syndrome (OHSS) is an exaggerated response to excess hormones and is also one of the life-threatening iatrogenic complications which is associated with ovulation induction. This syndrome usually occurs in women who receive injectable hormones for the stimulation of egg devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Manalai, Gulparkha, Shirzai, Asadullah, Aalemi, Ahmad Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403006/
https://www.ncbi.nlm.nih.gov/pubmed/34466037
http://dx.doi.org/10.2147/IMCRJ.S318485
_version_ 1783745925634588672
author Manalai, Gulparkha
Shirzai, Asadullah
Aalemi, Ahmad Khalid
author_facet Manalai, Gulparkha
Shirzai, Asadullah
Aalemi, Ahmad Khalid
author_sort Manalai, Gulparkha
collection PubMed
description Ovarian hyperstimulation syndrome (OHSS) is an exaggerated response to excess hormones and is also one of the life-threatening iatrogenic complications which is associated with ovulation induction. This syndrome usually occurs in women who receive injectable hormones for the stimulation of egg development in the ovaries. This study describes a rare case of moderate ovarian hyperstimulation syndrome which has been managed and treated with high-dose cabergoline. The patient was diagnosed in the Medical Imaging and Radiation Sciences Department of Kabul University of Medical Sciences and treated in Shahrara Teaching Hospital. A 26-year-old woman was diagnosed with the development of bilateral moderate ovarian hyperstimulation syndrome after receiving clomiphene citrate in dose of 100 mg BID on day 5 of period and Human Chorionic Gonadotropin (HCG) 10,000 units for egg release on day 14 of period. The patient was given a high dose of cabergoline. The dose was adjusted to 1 mg/day for eight days since she was diagnosed with ovarian hyperstimulation syndrome. Consequently, the main outcome of our intervention was complete resolution of OHSS as well as complete recovery of the patient. As a result, it is concluded that the high dose of cabergoline prevents and reduces the occurrence, prolongation, and severity of ovarian hyperstimulation syndrome. However, more assessments through randomized controlled trials regarding the efficacy and safety of cabergoline doses and treatment duration for treatment and preventive purposes are required.
format Online
Article
Text
id pubmed-8403006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84030062021-08-30 High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report Manalai, Gulparkha Shirzai, Asadullah Aalemi, Ahmad Khalid Int Med Case Rep J Case Report Ovarian hyperstimulation syndrome (OHSS) is an exaggerated response to excess hormones and is also one of the life-threatening iatrogenic complications which is associated with ovulation induction. This syndrome usually occurs in women who receive injectable hormones for the stimulation of egg development in the ovaries. This study describes a rare case of moderate ovarian hyperstimulation syndrome which has been managed and treated with high-dose cabergoline. The patient was diagnosed in the Medical Imaging and Radiation Sciences Department of Kabul University of Medical Sciences and treated in Shahrara Teaching Hospital. A 26-year-old woman was diagnosed with the development of bilateral moderate ovarian hyperstimulation syndrome after receiving clomiphene citrate in dose of 100 mg BID on day 5 of period and Human Chorionic Gonadotropin (HCG) 10,000 units for egg release on day 14 of period. The patient was given a high dose of cabergoline. The dose was adjusted to 1 mg/day for eight days since she was diagnosed with ovarian hyperstimulation syndrome. Consequently, the main outcome of our intervention was complete resolution of OHSS as well as complete recovery of the patient. As a result, it is concluded that the high dose of cabergoline prevents and reduces the occurrence, prolongation, and severity of ovarian hyperstimulation syndrome. However, more assessments through randomized controlled trials regarding the efficacy and safety of cabergoline doses and treatment duration for treatment and preventive purposes are required. Dove 2021-08-24 /pmc/articles/PMC8403006/ /pubmed/34466037 http://dx.doi.org/10.2147/IMCRJ.S318485 Text en © 2021 Manalai et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Manalai, Gulparkha
Shirzai, Asadullah
Aalemi, Ahmad Khalid
High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report
title High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report
title_full High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report
title_fullStr High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report
title_full_unstemmed High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report
title_short High Dose Cabergoline in Management of Bilateral Ovarian Hyperstimulation Syndrome: A Case Report
title_sort high dose cabergoline in management of bilateral ovarian hyperstimulation syndrome: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403006/
https://www.ncbi.nlm.nih.gov/pubmed/34466037
http://dx.doi.org/10.2147/IMCRJ.S318485
work_keys_str_mv AT manalaigulparkha highdosecabergolineinmanagementofbilateralovarianhyperstimulationsyndromeacasereport
AT shirzaiasadullah highdosecabergolineinmanagementofbilateralovarianhyperstimulationsyndromeacasereport
AT aalemiahmadkhalid highdosecabergolineinmanagementofbilateralovarianhyperstimulationsyndromeacasereport